Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
PRI-724 is a Wnt signaling pathway inhibitor which antagonistically inhibits the recruiting of beta-catenin with its coactivator CBP, thereby inhibiting tumor growth (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PRI-724||CTNNB1 Inhibitor 26||PRI-724 is a Wnt signaling pathway inhibitor which antagonistically inhibits the recruiting of beta-catenin with its coactivator CBP, thereby inhibiting tumor growth (PMID: 31550723).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT01606579||Phase Ib/II||Cytarabine + PRI-724 Dasatinib + PRI-724 PRI-724||Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies||Completed||USA||0|
|NCT01302405||Phase I||PRI-724||Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors||Terminated||USA||0|
|NCT02413853||Phase II||Bevacizumab PRI-724 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab||Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer||Withdrawn||USA||0|